Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions
March 18, 2019 09:20 ET
|
Esperion Therapeutics, Inc.
–Study 2 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP––Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Adverse Event Profile was...
Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine
March 13, 2019 17:05 ET
|
Esperion Therapeutics, Inc.
– Study 1 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP –– Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Did Not Lead to Higher...
Esperion to Participate in Upcoming Investor Conferences
March 04, 2019 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient,...
Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions
March 04, 2019 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the results from Study 2 (1002-047, also known as CLEAR Wisdom, a pivotal Phase 3 study) of bempedoic...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2018 Financial Results
February 28, 2019 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient,...
Esperion Announces Submissions of Two NDAs and Official Completion of Two MAA Validations for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
February 28, 2019 07:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that the company has successfully completed important and key global marketing applications including the...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 22, 2019 17:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective,...
Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe
January 04, 2019 07:00 ET
|
Esperion Therapeutics, Inc.
– Esperion to Receive $300 Million in Upfront and Near-term Milestones –– Up to $900 Million in Total Milestones –– Substantial Tiered Royalties –– Esperion Partnering with...
Esperion to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 02, 2019 16:15 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Michigan, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Announces Late-Breaking Oral Presentation of Final Study 3 Results (1002-046) of Bempedoic Acid at the American Heart Association Scientific Sessions 2018
November 10, 2018 08:15 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 10, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), today announced that the final Phase 3 results from Study 3 (1002-046, also known as CLEAR Serenity) were presented at the...